News|Articles|March 9, 2026

FAQs: Navigating the AUA's 2025 Guideline on Chronic Pelvic Pain in Men

Author(s)Hannah Clarke

These FAQs outline key recommendations from the AUA's guideline on chronic pelvic pain in men.

In April 2025, the American Urological Association (AUA) released its Guideline on Chronic Pelvic Pain in Men, covering the evaluation and treatment of men who present with chronic pelvic pain, including chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and chronic scrotal content pain (CSCP). The guideline comprises 44 recommendations spanning patient evaluation (including confusable disorders for CP/CPPS and the differential diagnosis of scrotal pathology), pelvic floor myalgia and the role of pelvic floor physical therapy, management approaches grounded in shared decision-making and multidisciplinary care, and research gaps and potential future treatment options.

In a conversation with Amy Pearlman, MD, on Pearls and Perspectives, Susan MacDonald, MD, reflected on the recommendations and how she applies them in practice. The following FAQs summarize key guideline statements alongside her perspective.

1. What should the initial evaluation of a man with chronic pelvic pain include?

The guideline calls for a comprehensive history, complete review of symptoms, physical examination, and laboratory studies to document the symptoms and signs of chronic pelvic pain, as well as screening for concurrent pelvic pathology and exclusion of confusable disorders (Clinical Principle). Clinicians may use validated questionnaires to assess pain, urinary symptoms, and quality of life (Clinical Principle), and should discuss psychosocial health, including anxiety, depression, major life stress, and effects on daily functioning (Clinical Principle).

A thorough scrotal examination is recommended, and a scrotal ultrasound may be performed (Clinical Principle). Cystoscopy, urodynamics, and/or imaging may be used when the diagnosis is unclear (Clinical Principle).

Because many patients have seen several clinicians before reaching a urologist with an interest in pelvic pain, MacDonald said she does not rely on prior workups, noting "I always start from scratch. I consider my visit with a patient almost like a second opinion every single time, because they have seen other providers.”

2. What does the guideline recommend regarding a transrectal pelvic floor examination?

Clinicians should perform transrectal digital palpation of the pelvic floor muscles in men to identify tenderness suggestive of pelvic floor myalgia (Expert Opinion).

MacDonald described several clinical clues that point toward pelvic floor dysfunction in a patient with testicular pain. Voiding symptoms such as hesitancy, straining, or a weak stream with normal findings on cystoscopy or retrograde urethrogram suggest a functional, rather than anatomical, obstruction.

According to MacDonald, patients with pelvic floor dysfunction are about 6 times more likely to report bowel symptoms, and pain with ejaculation is nearly pathognomonic for either a stricture or pelvic floor dysfunction. When testicular pain is accompanied by bowel, bladder, or sexual symptoms, she said, the cause is almost always pelvic floor dysfunction, and she screens for these symptoms before considering neuropathic pain medications or procedures.

3. How should urologists screen for neurologic, musculoskeletal, and orthopedic contributors?

The guideline directs clinicians to screen for neurologic, musculoskeletal, and orthopedic abnormalities of the pelvis, hip, and lower spine, with referral to an appropriate specialist when abnormalities are identified (Expert Opinion).

Because a full neurologic examination is time-intensive, MacDonald uses a streamlined approach: she asks about tingling in the fingers and toes, asks what activities patients perform that may affect their body and spine, performs a genital examination, and assesses sensation at several points and hand strength. She uses pain when climbing stairs as a screening question for hip involvement and performs a more detailed assessment only when she suspects spinal or hip pathology.

4. How does the guideline distinguish among IC/BPS, CP/CPPS, and CSCP?

The guideline outlines 3 diagnoses to consider, each as Expert Opinion:

  • Interstitial cystitis/bladder pain syndrome (IC/BPS): an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the bladder, associated with lower urinary tract symptoms lasting more than 6 weeks, in the absence of infection or other identifiable causes.
  • CP/CPPS: chronic perineal pain, bilateral scrotal content pain, penile pain, suprapubic pain, dysuria, or pain with ejaculation.
  • CSCP: unilateral chronic scrotal pain in the absence of other pelvic sites of pain or urinary symptoms. In patients with isolated unilateral CSCP, clinicians may perform a diagnostic spermatic cord block and/or ilioinguinal block.

5. When should clinicians use the 2-glass or 4-glass localization test?

A prostate massage, 2-glass, or 4-glass localization test may be performed if there is diagnostic uncertainty in distinguishing chronic bacterial prostatitis from CP/CPPS (Expert Opinion). The guideline does not mandate these tests.

6. What principles guide the overall management approach?

The guideline recommends that treatment decisions be made through shared decision-making, with patients informed of the risks, potential benefits, and alternatives, and that initial treatment typically be nonsurgical (Clinical Principle). Clinicians should periodically reassess treatment efficacy, discontinue ineffective treatments, and reconsider the diagnosis if multiple approaches fail (Clinical Principle). A multimodal and multidisciplinary approach may be used, with referral to pain management discussed if pain control is inadequate (Clinical Principle).

MacDonald noted, "You have to listen to the patient and pair with them to direct their therapy," she said.

7. How should psychosocial factors be addressed?

Clinicians should encourage patients who express significant distress secondary to chronic pelvic pain to seek treatment for mental health needs and should discuss family, spousal, and/or local support systems (Clinical Principle). Clinicians should not send patients for psychological interventions or dismiss them for somatization before appropriate medical evaluation (Clinical Principle).

MacDonald stressed that many patients arrive skeptical after seeing multiple clinicians and receiving conflicting explanations. To build trust, she listens closely, documents the patient's own description of symptoms, and confirms it with them.

"Write down what is actually happening, repeat it back to them, validate that their pain is real. And this is in the guidelines. It is not in their head. They have been told it's in their head," she said. She explains to patients that stress can manifest physically in different ways, such as headaches or neck tension, and that some people carry it in the pelvic floor; the pain is real, but stress can worsen it.

8. What pharmacologic options does the guideline include for CP/CPPS?

The guideline includes the following pharmacologic options for CP/CPPS:

  • Alpha-blockers: should be offered to patients with voiding symptoms (Moderate Recommendation; Evidence Level: Grade B).
  • 5-alpha reductase inhibitors: may be prescribed for patients who also have voiding symptoms from benign prostatic hyperplasia (BPH) or an enlarged prostate as determined by imaging or prostate-specific antigen level (Expert Opinion).
  • Anti-inflammatory agents, including NSAIDs: may be prescribed as part of a multimodal pain management strategy (Conditional Recommendation; Evidence Level: Grade B).
  • Daily tadalafil: may be prescribed for prostatitis symptoms with or without concomitant erectile dysfunction (Conditional Recommendation; Evidence Level: Grade B).
  • Analgesics (eg, urinary analgesics, acetaminophen, non-opioid medications): may be prescribed after counseling on risks and benefits (Clinical Principle).
  • Neuropathic pain medications, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and gabapentinoids (Conditional Recommendation; Evidence Level: Grade C).
  • Phytotherapeutics, including saw palmetto, quercetin, and pollen extract, to improve pain, voiding symptoms, and quality of life (Conditional Recommendation; Evidence Level: Grade B).

MacDonald noted that adverse effects can steer treatment selection among these options.

9. What nonpharmacologic therapies are recommended for CP/CPPS?

The guideline includes several nonpharmacologic options for CP/CPPS:

  • Lifestyle modification, including dietary changes and aerobic exercise (Conditional Recommendation; Evidence Level: Grade C).
  • Low-intensity extracorporeal shockwave therapy (ESWT): clinicians should discuss this option (Moderate Recommendation; Evidence Level: Grade A).
  • Transcutaneous electrical nerve stimulation (TENS) for pain control (Conditional Recommendation; Evidence Level: Grade B).
  • Acupuncture (Conditional Recommendation; Evidence Level: Grade B).
  • Cognitive behavioral therapy as an adjunct to other therapeutic interventions (Conditional Recommendation; Evidence Level: Grade C).

10. What is the role of pelvic floor physical therapy?

In men with pelvic floor myalgia or abdominopelvic muscle myalgia, clinicians may offer individualized manual physical therapy techniques, such as internal and external myofascial release of affected tissues (Conditional Recommendation; Evidence Level: Grade C). Clinicians may also use electromyography biofeedback training to improve pelvic floor muscle resting tone and relaxation time in patients with increased pelvic floor muscle tone (Expert Opinion).

11. What treatment options are available for CSCP, including post-vasectomy pain syndrome?

For CSCP, clinicians should discuss lifestyle modification (Clinical Principle) and may prescribe pharmacologic pain management agents such as acetaminophen, NSAIDs, tricyclic antidepressants, gabapentinoids, and non-opioid options as part of multimodal therapy (Clinical Principle). In antibiotic-naive patients, a single 10-day trial of antimicrobials may be prescribed (Clinical Principle). Additional options include:

  • Microsurgical denervation of the spermatic cord, especially in patients who previously responded to a spermatic cord block (Conditional Recommendation; Evidence Level: Grade C).
  • Vasectomy reversal (vasovasostomy) for post-vasectomy pain syndrome (Expert Opinion).
  • Acupuncture and pelvic floor physical therapy (Expert Opinion).
  • Transcutaneous electrical nerve stimulation (Conditional Recommendation; Evidence Level: Grade C).
  • Epididymectomy for pain and tenderness focal to the epididymis after failure of conservative therapies (Expert Opinion).
  • Inguinal (not scrotal) orchiectomy with removal of the entire spermatic cord (Expert Opinion).
  • Consultation with a pain management specialist for options such as neuromodulation, neurostimulators, or spinal blocks if all treatment options fail (Expert Opinion).

12. Which treatments should not be offered?

The guideline identifies several treatments that should not be offered to patients with chronic pelvic pain:

  • Repeated courses of antimicrobial therapy for CP/CPPS or CSCP in the setting of negative urine cultures, negative tests for sexually transmitted infection, or following a vasectomy (Clinical Principle).
  • Surgical procedures on the prostate (radical prostatectomy and outlet procedures for BPH) to relieve pelvic pain, although such procedures may be discussed as part of multimodal therapy in patients with coexisting pain and prostate cancer or bladder outlet obstruction (Expert Opinion).
  • Long-term systemic (oral) glucocorticoids to treat pelvic pain (Expert Opinion).
  • Referral for psychological interventions or dismissal for somatization before appropriate medical evaluation (Clinical Principle).

______

REFERENCES

1. Lai HH, Pontari MA, Argoff CE, et al. Diagnosis and Management of Male Chronic Pelvic Pain (Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Chronic Scrotal Content Pain): AUA Guideline (2025). J Urol. https://www.auanet.org/guidelines-and-quality/guidelines/male-chronic-pelvic-pain

2. American Urological Association releases new guideline on chronic pelvic pain in men. News release. American Urological Association. April 17, 2025. Accessed March 9, 2026. https://www.auanet.org/about-us/media-center/aua-press-center/american-urological-association-releases-new-guideline-on-chronic-pelvic-pain-in-men


Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.